

1 A unique cytotoxic CD4⁺ T cells signature defines critical COVID-19

2 Sarah Baird^{1,2†}, Caroline L. Ashley^{1,2†}, Felix Marsh-Wakefield^{1,3}, Sibel Alca^{1,2}, Thomas M.
3 Ashhurst^{1,4}, Angela L. Ferguson¹, Hannah Lukeman^{1,2}, Claudio Counoupas^{1,5}, Jeffrey J. Post⁶,
4 Pamela Konecny⁷, Adam Bartlett^{8,9,10}, Marianne Martinello⁸, Rowena A. Bull^{8,9}, Andrew Lloyd⁸,
5 Alice Grey¹¹, Owen Hutchings¹¹, Umaimainthan Palendira¹, Warwick J. Britton^{5,12}, Megan
6 Steain^{1,2*} & James A. Triccas^{1,2*}

7

8 ¹School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney,
9 Camperdown, NSW, Australia

10 ²Sydney Institute for Infectious Diseases and the Charles Perkins Centre, The University of Sydney,
11 Camperdown, NSW, Australia

12 ³Vascular Immunology Unit, The University of Sydney, Sydney, New South Wales, Australia

13 ⁴Sydney Cytometry Core Research Facility, Charles Perkins Centre, Centenary Institute and The
14 University of Sydney

15 ⁵Tuberculosis Research Program, Centenary Institute, Sydney, NSW, Australia

16 ⁶Prince of Wales Clinical School, UNSW Australia, Sydney, NSW Australia

17 ⁷St George Hospital, Sydney, New South Wales, Australia

18 ⁸The Kirby Institute, UNSW, Sydney, NSW, Australia

19 ⁹School of Biomedical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia

20 ¹⁰Sydney Children's Hospital, Sydney, NSW, Australia

21 ¹¹RPA Virtual Hospital, Sydney Local Health District, Sydney, NSW, Australia.

22 ¹²Department of Clinical Immunology, Royal Prince Alfred Hospital, Camperdown, Australia

23

24 * Address correspondence to James A. Triccas; jamie.triccas@sydney.edu.au or Megan Steain;
25 megan.steain@sydney.edu.au

26

27 †These authors contributed equally to this work

28

29

30 Running title: Cytotoxic T cells and COVID-19 severity

31 **Abstract**

32 **Background and objectives.** SARS-CoV-2 infection causes a spectrum of clinical disease
33 presentation, ranging from asymptomatic to fatal. While neutralising antibody (NAb) responses
34 correlate with protection against symptomatic and severe infection, the contribution of the T cell
35 response to the resolution or progression of disease is still unclear. Optimal protective immunity
36 may require activation of distinct immune pathways. As such, defining the contribution of
37 individual T cell subsets to disease outcome is imperative to inform the development of next-
38 generation COVID-19 vaccines. To address this, we performed immunophenotyping of T cell
39 responses in unvaccinated individuals, representing the full spectrum of COVID-19 clinical
40 presentation. **Methods.** Spectral cytometry was performed on peripheral blood mononuclear cell
41 samples from patients with PCR-confirmed SARS-CoV-2 infection. Computational and manual
42 analyses were used to identify T cell populations associated with distinct disease states through
43 unbiased clustering, principal component analysis and discriminant analysis. **Results.** Critical
44 SARS-CoV-2 infection was characterised by an increase in activated and cytotoxic CD4⁺ (CTL)
45 cells of a T follicular helper (T_{FH}) or effector memory re-expressing CD45RA (T_{EMRA}) phenotype.
46 These CD4⁺ CTLs were largely absent in those with less severe disease. In contrast, those with
47 asymptomatic or mild disease were associated with high proportions of naïve T cells and reduced
48 expression of activation markers. **Conclusion.** Highly activated and cytotoxic CD4⁺ T cell
49 responses may contribute to cell-mediated host tissue damage and progression of COVID-19.
50 Potential for induction of these detrimental T cell responses should be considered when developing
51 and implementing effective COVID-19 control strategies.

52

53 **Keywords.** SARS-CoV-2, COVID-19, T cells, Spectral Cytometry, CD4-CTLs.

54 **Introduction**

55 The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been ongoing
56 since March of 2020. As of February 2023, over 754 million cases of SARS-CoV-2 infection and
57 6.83 million fatalities from coronavirus disease 2019 (COVID-19) have been reported.¹ While
58 several vaccines are now available for use, SARS-CoV-2 remains a leading cause of infectious
59 disease death globally. One of the major challenges with SARS-CoV-2 infection is the spectrum of
60 COVID-19 clinical presentation, ranging from asymptomatic to fatal. It is thought that more severe
61 disease results from a dysregulated immune response to infection; however, variability in this
62 immune dysfunction between individuals has limited understanding of the correlates of disease
63 severity. Developing a more comprehensive understanding of the immune response across the
64 spectrum of COVID-19 clinical presentation will help to differentiate protective from pathogenic
65 immune responses. This is essential to inform the development of next-generation therapies and
66 vaccines against SARS-CoV-2, with improved longevity and efficacy against newly emerging
67 variants of concern (VOC).

68 The key correlate of protective immunity against infection and severe disease in COVID-19 is
69 neutralising antibody responses (NAb).^{2,3} As such, the factors that contribute to breakthrough
70 infection following vaccination centre around humoral immune responses, such as waning NAb
71 titres, and antibody escape mutations on globally dominant VOC.⁴⁻⁹ The T cell response appears to
72 have greater longevity than detectable NAb, with sustained response to antigen stimulation
73 demonstrated >1-year post-infection.^{10,11} Additionally, the dominant T cell epitopes do not overlap
74 with areas of high mutation on variant viruses, and as a result the T cell response is preserved
75 against antibody-escape VOC.^{9,12-16} Considering the limitations of current vaccines, it has been
76 suggested that the long-lived T cell response against SARS-CoV-2 variants may contribute to
77 protective immunity in the absence of a robust humoral immune response.^{12,13,16} While NAb
78 responses have been shown to tightly correlate with protection against disease, no such correlation

79 has been shown with the T cell response to SARS-CoV-2.¹⁷ There is evidence that polyfunctional
80 and cross-reactive T cell responses to seasonal coronaviruses are associated with milder disease and
81 faster viral clearance.^{18–20} However, several studies have also described an expansion of highly
82 activated T cells in severe COVID-19, that could potentially contribute to excessive inflammatory
83 immune responses and host-tissue damage.^{21–23} As such, whether T cells play a protective or
84 pathogenic role in COVID-19 is still unresolved.

85

86 To better define the role of T cell subsets, we performed an explorative investigation into T cell
87 phenotypes across the clinical spectrum of COVID-19 presentation, utilising an unbiased analysis
88 approach with a T-cell-centric high-dimensional cytometry panel. We report that critical COVID-
89 19 infection is characterised by a shift from naïve T cell phenotypes to an expansion of cytotoxic
90 CD4⁺T lymphocyte subsets.

91 **Results**

92 **The T cell compartment distinguishes critical SARS-CoV-2 infection from other disease** 93 **states.**

94 To obtain a global view of the T cell response within and between disease states, peripheral blood
95 mononuclear cells (PBMCs) were isolated from the blood of patients and spectral cytometry was
96 performed using a T cell-centric antibody panel. Initially, T cell populations were manually gated
97 (Figure s1) and differences in the proportion of each population between patients were identified by
98 an unsupervised Principal Component Analysis (PCA), where each data point represents one patient
99 sample (Figure 1a). When the COVID-19 severity of each patient was superimposed onto the PCA
100 patients with critical infection separated distinctly across the first component (dim 1, accounted for
101 31.8% of the variance) from most other patient samples (Figure 1a). Visualisation of the
102 contribution of each T cell population proportion to the principal components revealed that the
103 expression of activation/proliferation markers HLA-DR, Granzyme B (GZMB), Perforin (PFN),
104 and Ki-67 on central memory (T_{CM}), effector memory (T_{EM}), and effector memory re-expressing
105 CD45RA (T_{EMRA}) contribute to the separation of samples in dimension 1 (Figure 1b). Furthermore,
106 the proportions of these activated, memory $CD4^+$ and $CD8^+$ T cell subsets were negatively
107 correlated to those of $CD4^+$ and $CD8^+$ naïve T cells (T_N) (Figure 1b).

108

109 **Metaclusters of cytotoxic $CD4^+$ T cells differentiate critical and severe SARS-CoV-2 infection**

110 To determine which T cell populations may be implicated in progression from severe to critical
111 COVID-19, patients in those groups were selected for further analysis. To fully capture the
112 heterogeneity of activation and cytotoxic marker expression in the T cell compartment of these
113 patients, unbiased clustering was performed. FlowSOM clustering was set to create 25 metaclusters
114 (Mcs) and fast interpolation-based t-SNE (Fit-SNE) was used to visualise the proportion of each Mc
115 (Figure 2a & b), with a heatmap generated for phenotyping (Figure 2c). As the T-cell panel
116 included markers to define conventional $CD4^+$ and $CD8^+$ subsets, $CD4^+CD8^-$ Mcs (7, 8, 11, 14 and

117 22) were excluded and a Partial Least Squares Discriminant Analysis (PLS-DA) was performed to
118 identify the Mcs that contribute to variance between severe and critical infection. Like the PCA
119 (Figure 1b) the PLS-DA revealed distinct separation of severe and critical patients, with 43.6% of
120 the variance in the proportion of Mcs accounted for in the first component (Figure 2d). Mc25, 15,
121 and 5 were enriched in critical infection, with Mc23 and 2 enriched in severe infection patients
122 (Figure 2e & b). To confirm that the difference in these Mcs were not an artefact of the
123 unsupervised nature of the PLS-DA, unpaired Mann-Whitney U-tests comparing the proportions of
124 each Mc between severe and critical patients was performed. Mc25 (GZMB⁺PFN⁺ CD4⁺ CD45RO⁻,
125 CCR7⁻), Mc15 (GZMB⁺PFN⁺ CD4⁺ CD45RO⁺, CCR7⁻), and Mc5 (HLA-DR⁺ CD4⁺ CD45RO⁺,
126 CCR7⁺) were significantly enriched in critical compared to severe infection (Figure 2f). While the
127 expression of CCR7 and CD45RO on Mc25 and 15 suggest a T_{EMRA} and T_{EM} phenotype
128 respectively, these Mcs also appeared to express intermediate levels of CXCR5 on the heatmap, a
129 feature of CD4⁺ T_{FH} cells (Figure 2c). However, Mcs 25 and 15 displayed a spectrum of expression
130 of CXCR5 (Figure s2) and thus this analysis did not allow definitive determination of T_{FH}
131 phenotype. Therefore, Mc25 and 15 represent cytotoxic CD4⁺ T lymphocyte subsets, with Mc5
132 being a population of activated T_{CM} cells. The proportion of Mc23 (CD8⁺ CD45RO⁻, CCR7⁺) and
133 Mc2 (CD4⁺ CD45RO⁻, CCR7⁺) were significantly greater in severe patients than critical,
134 representing non-activated naïve (T_N) CD8⁺ and CD4⁺ T cells, respectively (Figure 2f). This
135 analysis suggests an expansion of activated and cytotoxic CD4⁺ T cells populations and a decrease
136 in the proportion of T_N cell subsets is involved in progression from severe to critical SARS-CoV-2
137 infection.

138

139 **Cytotoxic CD4⁺ T lymphocytes are characteristic of disease progression**

140 As the proportions of naïve and memory T cells were negatively correlated (Figure 1c), the
141 distribution of naïve/memory subsets were further explored in the CD4⁺ non-T_{FH} and CD8⁺ T cell
142 compartments by manual gating on CD45RO and CCR7 (Figure 3a). Critical patients exhibited

143 increased proportions of CD8⁺ T_{EMRA} cells and a reduction in the proportion of CD4⁺ T_N cells,
144 compared to both mild and severe disease (Figure 3b). In contrast, the T cell compartments in
145 asymptomatic, mild, moderate, and severe patients were composed of comparable proportions of T_N
146 CD4⁺ and CD8⁺ cells. While the proportion of CD4⁺ T_{EMRA} cells was not significantly elevated,
147 critical patients had increased expression of the activation marker HLA-DR on CD4⁺ T_{EMRA} cells
148 compared to those with asymptomatic or mild disease (Figure 3c). There was also a notable increase
149 in the proportion of CD8⁺ T_{EMRA} cells expressing the activation marker PD-1 as disease severity
150 worsened (Figure 3c). As Mc25 and 15 could not clearly be defined as T_{FH} cell populations,
151 manually gated CXCR5^{hi} CD4⁺ T_{FH} cells were selected for further analysis. While the proportion of
152 total T_{FH} and CCR7⁺PD-1⁻ T_{FH} cells was not significantly different between groups, the proportion
153 of circulating PD-1⁺CCR7⁻ T_{FH} cells (cT_{FH}) was elevated in critical infection (Figure 3d).

154

155 The computational analyses in Figures 1 and 2 revealed distinct populations of cytotoxic
156 (GZMB⁺PFN⁺) CD4⁺ T cell subsets enriched in critical disease. As cytotoxic CD8⁺ T cells have
157 been correlated with disease severity and mortality in COVID-19,²² the proportion of GZMB⁺PFN⁺
158 CD4⁺ and CD8⁺ subsets were of interest to investigate further. As a proportion of lymphocytes,
159 critical patients had expanded populations of cytotoxic CD4⁺, but not CD8⁺ T cells. Cytotoxic CD4⁺
160 T cells made up a mean of 3.68% of the lymphocyte compartment in critical infection patients, and
161 between 0.41-1.28% in all other disease states (Figure 4a). To delineate the subsets of cytotoxic
162 CD4⁺ T cells contributing to this, the proportions of GZMB⁺PFN⁺ T_{FH} and CD4⁺ non-T_{FH} cells were
163 compared across disease states. Both these subsets were significantly elevated in critical disease,
164 and as such the phenotype of subpopulations within these subsets were explored further (Figure 4b).
165 Of the CD4⁺ non-T_{FH} cell compartment, there was a higher proportion of CD4⁺ T_{EMRA} cells
166 expressing GZMB⁺PFN⁺ cells in critical infection (Figure 4c). This was in line with the
167 predominant T_{EM} and T_{EMRA} phenotype of cytotoxic compared to total CD4⁺ non-T_{FH} cells, which
168 were largely of a T_N and T_{CM} phenotype (Figure 4d). Similarly, cytotoxic CD4⁺ T_{FH} cells were

169 almost exclusively of a CCR7⁺PD-1⁺ cT_{FH} phenotype and total T_{FH} cells were predominantly of a
170 CCR7⁺PD-1⁻ phenotype (Figure 4e). Finally, the proportion of cytotoxic CD4⁺ and CD8⁺ T cells
171 was correlated to determine whether CD4⁺ cytotoxicity may be a compensating for CD8⁺ T cell
172 exhaustion. However, these two populations correlated positively with each other (p = 0.0039;
173 Figure 4f). From these data it appears that the expansion of cytotoxic CD4⁺ cT_{FH} and T_{EMRA}
174 populations during SARS-CoV-2 infection is unique to critical disease.
175

176 Discussion

177 Characterising immune responses that associate with different disease severities of COVID-19 may
178 help to define protective immune responses to SARS-CoV-2 and guide the rational development of
179 next-generation vaccines. This study provides a phenotypic analysis of the T cell response in
180 patients experiencing asymptomatic to critical SARS-CoV-2 infection. We confirm that the T cell
181 compartment is distinctly altered in critical SARS-CoV-2 infection, defined by an expansion of
182 effector memory subsets, and increased expression of activation and cytotoxic functional markers
183 on CD4⁺ T cells. These data suggest a potentially pathogenic role of cytotoxic CD4⁺ CTLs in the
184 progression of COVID-19.

185

186 CD4⁺ T cells are well-established critical responders in viral infection; however, CTL function is
187 more commonly associated with CD8⁺ T cell populations. As such, it is of interest that the top Mcs
188 associated with the progression of disease from severe to critical were activated and cytotoxic CD4⁺
189 T cell populations (Figure 2). CD4⁺ T cells can mediate host-cell death through secretion of
190 granzyme B and perforin^{24,25}, and CD4⁺ CTLs have been identified during viral infections including
191 human immunodeficiency virus (HIV), human cytomegalovirus (CMV), Epstein Barr virus (EBV),
192 influenza, dengue virus and more recently SARS-CoV-2.²⁶ In patients with COVID-19, CD4⁺ T
193 cells expressing high levels of *PFNI*, *GZMB* and *GZMH* transcripts have been identified previously
194 by scRNA-seq to be enriched in hospitalised compared to non-hospitalised COVID-19 patients.²⁷
195 The data provided in this current study describes an increase in CD4⁺ CTLs, and a unique
196 expansion of GZMB⁺PFN⁺ CD4 T_{EMRA} cells during critical infection at the level of protein
197 expression. While the circulating T cell populations have been analysed in this cohort, high
198 infiltration of CD4⁺ CTLs, as well as CD8⁺ CTLs, have also been reported in the lung parenchyma
199 of severely ill COVID-19 patients.^{24,28} The elevated expression of HLA-II in the respiratory
200 epithelium provides a potential mechanistic basis for the role of CD4⁺ CTLs in the profound host
201 tissue damage associated with SARS-CoV-2 acute respiratory distress syndrome (ARDS).²⁴

202

203 In the CD4 T_{FH} cell compartment, critical patients also exhibited increased proportions of cytotoxic
204 cells, which were predominantly of a CCR7PD-1⁺ phenotype; such cells have been previously
205 described as circulating T_{FH} (cT_{FH}) cells.²⁹ Cytotoxic T_{FH} cells have been shown to induce B cell
206 death and to correlate negatively with antibody titres in recurrent Strep A infection in children.³⁰
207 Post-mortem investigations have shown loss of germinal centre (GC) B cells and absence of GCs in
208 the lymph nodes of COVID-19 decedents.³¹ However, while cytotoxic cT_{FH} cells were elevated and
209 correlated negatively to anti-S1/S2 SARS-CoV-2 antibodies in hospitalised patients, this correlation
210 was not seen in non-hospitalised patients.²⁷ Conversely, antibody-secreting plasmablasts have been
211 correlated with mortality in COVID-19,²² and higher antibody responses are associated with more
212 severe disease.³² As there are limited studies investigating cytotoxic cT_{FH} in COVID-19, the
213 implications of cytotoxicity in cT_{FH} cells require further investigation to assess any potential
214 detrimental effect this cell type may have on antibody responses to SARS-CoV-2.

215

216 CD4⁺ T cell cytotoxicity has been proposed to be a compensatory mechanism to combat exhaustion
217 of CD8⁺ T cells, in which CD8⁺ CTL expression of GZMB and PFN decrease, and PD-1
218 increases.^{33,34} In contrast, no change in the proportion of CD8⁺ GZMB⁺PFN⁺ subsets was observed
219 here across disease severities. Moreover, PD-1 expression was not highlighted as a key variable in
220 the separation of disease states in the PCA. This suggests that if CD8⁺ CTL exhaustion was present
221 it was not a differentiating feature of disease progression. As such, the increased proportion of PD-
222 1⁺CD8⁺ T_{EMRA} cells in critical infection likely represents a phenotype of increased activation, rather
223 than functional exhaustion. In line with this view, previous studies have reported elevated
224 frequencies of hyperactivated CD8⁺ cells, defined by expression of HLA-DR⁺CD38⁺PD-1⁺TIM-3⁺,
225 in severe and critical SARS-CoV-2 infection.^{21,22} While no difference in cytotoxicity was reported
226 here, GZMB and PFN expression has been correlated with critical disease and mortality in COVID-
227 19.^{22,35-39} Rha et al., (2021) reported GZMB and PFN were expressed by almost all SARS-CoV-2-

228 specific multimer⁺ CD8⁺ T cells.⁴⁰ As such, enrichment for SARS-CoV-2 specific T cells may
229 provide more insight into the changes in proportion and phenotype of cytotoxic CD8⁺ T cells
230 between disease states. In combination with these studies, the data presented here suggest that
231 hyperactivated effector memory subsets of CD8⁺ T cells may contribute to COVID-19 progression.

232

233 Investigating the immune response in asymptomatic and mild disease can shed light on the immune
234 response that effectively controls viral replication and disease progression. Control of viral load by
235 T cells was demonstrated in B-cell depleted Rhesus Macaques⁴¹, and CD8⁺ T cell responses
236 correlated with better clinical outcome in patients with inborn errors in humoral immune responses
237 and B cell impairment in SARS-CoV-2 infection.^{42,43} In the current study, asymptomatic and mild
238 patients exhibited low frequencies of activated or cytotoxic cells, and a predominantly naïve
239 phenotype in both the CD4⁺ and CD8⁺ compartments. However, there is an inherent limitation to
240 investigating the peripheral immune response in a respiratory infection where localised
241 inflammation and resident immune cell responses may not be reflected in circulation.⁴⁴
242 Furthermore, this study did not investigate SARS-CoV-2-specific T cells, and as such a
243 proportionally smaller T cell response may be missed in these less severe disease states. It has been
244 shown previously that individuals with mild infection are less likely to have detectable SARS-CoV-
245 2-specific T cell responses.⁴⁵ In combination with the relative lack of a robust T cell response in
246 asymptomatic and mild disease here, this may question the necessity of a strong T cell response to
247 prevent the progression of COVID-19. This is consistent with the diverse polyclonal, less
248 differentiated SARS-CoV-2 specific T cell response observed in children with mild and
249 asymptomatic T cell response than the clonally expanded memory T cell response with markers of
250 cytotoxicity and exhaustion present in adults.⁴⁶ The protective capacity of T cells should be
251 investigated further to assess whether preserved T cell response against variant SARS-CoV-2
252 viruses provide protection against severe disease, as has been suggested previously.^{12,13,16}

253

254 Finally, there are several clinical variables that may confound this analysis, notably the impact of
255 age on the immune response to infection. The critical patients were older than asymptomatic and
256 mild patients which is reflective of the high median age of COVID-19 patients admitted to hospital
257 and ICU.⁴⁷ Age over 65 years is associated with a progressive decline in immune function
258 characterised by decreased thymic function, contraction of naive T cell populations, and perturbed
259 T cell function, such as reduced cytokine production and proliferative capacity.^{48,49} It has been
260 shown previously that SARS-CoV-2 immune dysregulation mimics that seen in age-related
261 immunosenescence.⁵⁰ Without age-matched patients, the impact of age cannot be extricated from
262 that of disease severity on the T cell response to SARS-CoV-2.

263

264 The data presented in our study add to our understanding of the contribution of T cell responses to
265 disease progression in SARS-CoV-2 infection. The distinct absence of a notable T cell response in
266 asymptomatic disease but expansion of cytotoxic CD4⁺ cT_{FH} and T_{EMRA} subset in critical disease,
267 suggest that CTLs may be contributing to host tissue damage and systemic inflammatory disease.
268 As such, the potentially detrimental role of T cell responses in COVID-19 should be considered in
269 the development of next-generation therapies and vaccines against SARS-CoV-2.

270 **Material and Methods**

271 **Patient Demographics**

272 SARS-CoV-2 PCR-positive patients and their household contacts were enrolled through the Royal
273 Prince Alfred (RPA) hospital COVID-19 clinic or virtual care system in March of 2020 (COVIMM
274 cohort). Ethics approval was granted by the RPA ethics committee, human ethics number X20-0117
275 and 2020/ETH00770. Verbal consent was given by all participants. Additional patients enrolled in
276 the COSIN study in June 2021 through seven hospital microbiology labs, and out-patient care units
277 across Sydney, Australia, as described by Balachandran et al. (2022) were also included. Ethics
278 approval was granted by Human Research Ethics Committees of the Northern Sydney Local Health
279 District and the University of New South Wales, NSW Australia (ETH00520), and written consent
280 was obtained from all patients.

281 SARS-CoV-2 infection was defined by a positive nasopharyngeal RT-PCR performed by accredited
282 laboratories within the Sydney Health District. Patients were classified as asymptomatic (n = 5),
283 mild (n = 18), moderate (n = 4), severe (n = 5), or critical (n = 3) (Supplementary Table 1). COVID-
284 19 disease severity as defined by the NIH guidelines
285 (<https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>). Patients were
286 classified as mild if their symptoms were self-manageable.

287 **Immunophenotyping by spectral cytometry**

288 Patient PBMCs were isolated from whole blood by Ficoll-density gradient separation, and
289 cryopreserved in Heat-inactivated FBS with 10% DMSO at -80°C. Cryopreserved PMBC samples
290 were thawed and diluted to a concentration of 1×10^6 live PMBCs in RPMI supplemented with
291 10% FCS and 100 ug/ml streptomycin and penicillin in a U-bottom 96-well plate. Cells were
292 washed in FACS buffer, dead cells labelled with LIVE/DEADTM Fixable Blue dye (Invitrogen) for
293 20 minutes at 4°C and washed twice in FACS buffer. Cells were stained with extracellular markers
294 (Supplementary Table 2; CD3-BUV395 (1:20), CD4-PerCPCy5.5 (1:100), CD8-BUV496 (1:100),

295 CD19-BV510 (1:50), CD56-BV605 (1:50), HLA-DR-BV650 (1:50), CD45RO-BV786 (1:50),
296 CD197-PECy7 (1:20), and CXCR5-AF647 (1:20) in FACS buffer for 20 minutes at 4°C. Cells were
297 then permeabilised and fixed with Transcription Factor Buffer Set (BD Pharmingen™) for 40
298 minutes at 4°C. Cells were washed then stained with intracellular markers (Supplementary Table 2)
299 PD-1-BV737 (1:50), Ki-67-BV711 (1:50), Perforin-PE (1:50), and Granzyme B-APC (1:20) in
300 Transcription Factor wash buffer (BD Pharmingen™). Anti-Mouse Ig, κ/Negative Control Particles
301 Set (BD™ CompBeads) were used for single stain controls and stained with corresponding
302 extracellular and intracellular stains. Fluorescent minus one (FMO) controls were included for
303 intracellular markers and stained at the concentration of patient samples at corresponding staining
304 times. The samples underwent a second fixation step with 4% paraformaldehyde for 30 minutes,
305 washed, and resuspended in 200 ml FACS buffer for acquisition. Patient samples and controls were
306 acquired using the 5-laser Cytex Aurora® Spectral Cytometer. Spectral unmixing was performed
307 using the inbuilt SpectroFlo® software after acquisition of unstained and single-stained controls and
308 before patient sample acquisition.

309 **Data Analysis**

310 Data analysis was performed in FlowJo v10.8.1, R v4.2.1, and GraphPad Prism v9. Dead cells,
311 doublets, and debris were excluded in FlowJo v10.8.1 by FSC-A, FSC-H, SSC-A, and
312 LIVE/DEAD dye (Figure S1). NKT and B cells were excluded by CD3⁺CD56⁺ and CD3⁻CD19⁺
313 phenotype, respectively. Compensation for unmixing errors was performed in FlowJo v10.8.1.
314 Irregularities in staining and acquisition between batches were controlled by matching gates on
315 control samples and applying identical gate lineage and functional marker expression within each
316 staining batch.

317 To control for the differences between staining batches, the Principal Component Analysis (Figure
318 1) was calculated using 38 overlapping CD3⁺ T cell populations that were manually gated in
319 FlowJo v10.8.1. CD4⁺ and CD8⁺ T cells were first divided into T_N (CCR7⁺CD45RO⁻), T_{CM}

320 (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), T_{EMRA} (CCR7⁻CD45RO⁻) subsets. The frequency of
321 CD4⁺ and CD8⁺ T_N, T_{CM}, T_{EM}, and T_{EMRA} subsets, and the cells expressing HLA-DR, PD-1,
322 GRZMB, PFN, and Ki-67 in the T_{CM}, T_{EM}, and T_{EMRA} subsets were included to assess the
323 significance of T cell function on disease status (Figure S2). Each population was calculated as a
324 proportion of its respective CD4⁺ or CD8⁺ T cell compartment, and these frequencies were used for
325 PCA analysis in R v4.2.1 using the Spectre package.⁵¹

326 For the comparison between severe and critical infection, the R package Spectre was utilised for
327 computational analyses (<https://www.ncbi.nlm.nih.gov/pubmed/33840138>). CD3⁺ T cells were
328 exported for each patient sample. FlowSOM clustering created 25 metaclusters. Fit-SNE
329 dimensionality reduction⁵² was run on subsampled data of 50,000 cells from severe and critical
330 groups to create a representative plot between disease states and a heatmap plot of cellular marker
331 expression on each metacluster was created using the pheatmap function. To identify contributions
332 to differences between severe and critical infection, a partial least squares discriminant analysis
333 (PLS-DA) was done.⁵³ To validate the phenotype of metaclusters, an FCS file of marker expression
334 on each metacluster was created using the write.files function in Spectre. This allowed for clear
335 analysis of marker expression for each metacluster in FlowJo v10.8. After exclusion of CD4⁻CD8⁻
336 FlowSOM metaclusters, PLS-DA was performed to identify the variability in proportion of
337 metaclusters between severe and critical disease. Validation of the statistical differences in
338 proportion of metaclusters between groups was performed in GraphPrism v9.

339 The difference between groups were analysed by two-sided paired Mann-Whitney U-test, and non-
340 parametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original
341 False Discovery Rate (FDR) method of Benjamini and Hochberg. Statistical significance between
342 groups in computational analyses were calculated with a permutation ANOVA, with correction for
343 multiple comparisons by FDR method. Statistical significance was set as $p \leq 0.05$.

344

345 **Data availability**

346 The datasets generated during and/or analysed during the current study are available from the
347 corresponding author on reasonable request.

348

349 **Acknowledgments**

350 This work was supported by MRFF COVID-19 Vaccine Candidate Research Grant 2007221
351 (J.A.T., C.C., M.S., A.L.F.). F.M.□W. and T.M.A. are supported by the International Society for
352 the Advancement of Cytometry (ISAC) Marylou Ingram Scholars program. COSIN cohort was
353 supported by Snow Medical Foundation as an investigator-initiated study. We acknowledge the
354 support of the University of Sydney Advanced Cytometry Facility. The authors thank the study
355 participants for their contribution to this research and the clinical staff who collected the samples.

356

357

358

359

360

361 **References**

- 362 1. WHO. WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int>. 2022.
- 363 2. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
364 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
365 infection. *Nat Med*. 2021; **27**: 1205–1211.
- 366 3. Cromer D, Steain M, Reynaldi A, Schlub TE, Sasson SC, Kent SJ, et al. Neutralising
367 antibodies predict protection from severe COVID-19. *Nat Comms*. 2023 In Press.
- 368 4. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced
369 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell*. 2021; **184**:
370 4220-4236.e13.
- 371 5. Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, van Eeckhoudt S, et al. Antibody titres
372 decline 3-month post-vaccination with BNT162b2. *Emerg Microbes Infect*. 2021; **10**: 1495-
373 1498.
- 374 6. Vanshylla K, di Cristanziano V, Kleipass F, Dewald F, Schommers P, Giesemann L, et al.
375 Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in
376 humans. *Cell Host Microbe*. 2021; **29**: 917-929.e4.
- 377 7. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, le Bert N, et al. Dynamics of SARS-CoV-
378 2 neutralising antibody responses and duration of immunity: a longitudinal study. *Lancet*
379 *Microbe*. 2021; **2**: 240-249
- 380 8. Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, et al. Durability of mRNA-
381 1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science (1979)*. 2021; **373**:
382 1372-1377.
- 383 9. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. SARS-
384 CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19
385 convalescent donors and vaccinees. *Sci Immunol*. 2021; **6**: 782-787.

- 386 10. Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H, et al. SARS-CoV-2-specific T cell
387 memory is sustained in COVID-19 convalescent patients for 10 months with successful
388 development of stem cell-like memory T cells. *Nat Commun.* 2021; **12**.
- 389 11. Lu Z, Laing ED, Pena DaMata J, Pohida K, Tso MS, Samuels EC, et al. Durability of SARS-
390 CoV-2–Specific T-Cell Responses at 12 Months Postinfection. *J Infect Dis.* 2021; **224**: 2010–
391 9.
- 392 12. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination
393 induces immunological T cell memory able to cross-recognize variants from Alpha to
394 Omicron. *Cell.* 2022; **185**: 847-859.e11.
- 395 13. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2
396 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.
397 *Cell Rep Med.* 2021; **2**: 100355.
- 398 14. Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad
399 CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. *Journal of*
400 *Clinical Investigation.* 2021; **131**: e149335
- 401 15. Boni C, Cavazzini D, Bolchi A, Rossi M, Vecchi A, Tiezzi C, et al. Degenerate CD8 Epitopes
402 Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out
403 From the SARS-CoV-2 Variants Storm. *Front Immunol.* 2021; **12**: 730051.
- 404 16. Nathan A, Rossin EJ, Kaseke C, Park RJ, Khatri A, Koundakjian D, et al. Structure-guided
405 T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. *Cell.* 2021; **184**: 4401-
406 4413.e10.
- 407 17. Kent SJ, Khoury DS, Reynaldi A, Juno JA, Wheatley AK, Stadler E, et al. Disentangling the
408 relative importance of T cell responses in COVID-19: leading actors or supporting cast? *Nat*
409 *Rev Immunol.* 2022; **28**: 387-397.

- 410 18. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al.
411 Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations
412 with Age and Disease Severity. *Cell*. 2020; **183**: 996-1012.e19.
- 413 19. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive features of
414 SARS-CoV-2-specific T cells predict recovery from severe COVID-19. *Cell Rep*. 2021; **36**:
415 109414.
- 416 20. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory
417 T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nat*
418 *Commun*. 2022; **13**: 80.
- 419 21. Laing AG, Lorenc A, del Molino del Barrio I, Das A, Fish M, Monin L, et al. A dynamic
420 COVID-19 immune signature includes associations with poor prognosis. *Nat Med*. 2020; **26**:
421 1623–35.
- 422 22. Kuchroo M, Huang J, Wong P, Grenier JC, Shung D, Tong A, et al. Multiscale PHATE
423 identifies multimodal signatures of COVID-19. *Nat Biotechnol*. 2022; **40**: 681-691.
- 424 23. Bergantini L, d’Alessandro M, Cameli P, Cavallaro D, Gangi S, Cekorja B, et al. NK and T
425 Cell Immunological Signatures in Hospitalized Patients with COVID-19. *Cells*. 2021; **10**:
426 3182.
- 427 24. Kaneko N, Boucau J, Kuo HH, Perugino C, Mahajan VS, Farmer JR, et al. Temporal changes
428 in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19.
429 *Clinical Immunology*. 2022; **237**: 108991.
- 430 25. Shenoy AT, Lyon De Ana C, Arafa EI, Salwig I, Barker KA, Korkmaz FT, et al. Antigen
431 presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier
432 immunity. *Nat Commun*. 2021; **12**: 5834.
- 433 26. Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CML. Cytotoxic CD4 T
434 Cells—Friend or Foe during Viral Infection? *Front Immunol*. 2017; **8**: 19.

- 435 27. Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, et al. Imbalance
436 of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. *Cell*. 2020;
437 **183**: 1340-1353.e16.
- 438 28. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-
439 mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive
440 study. *Lancet Infect Dis*. 2020; **20**: 1135–40.
- 441 29. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating Precursor
442 CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody
443 Responses upon Antigen Reexposure. *Immunity*. 2013; **39**: 770–81.
- 444 30. Dan JM, Havenar-Daughton C, Kendric K, Al-kolla R, Kaushik K, Rosales SL, et al.
445 Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving
446 antibody deficiency and aberrant TFH cells. *Sci Transl Med*. 2019; **11**: 3776.
- 447 31. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss of
448 Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. *Cell*. 2020;
449 **183**: 143-157.e13.
- 450 32. Sun J, Tang X, Bai R, Liang C, Zeng L, Lin H, et al. The kinetics of viral load and antibodies
451 to SARS-CoV-2. *Clinical Microbiology and Infection*. 2020; **28**: 1690.e1-1690.e4.
- 452 33. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion
453 of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). *Front Immunol*. 2020;
454 **11**: 827.
- 455 34. Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subset of CD4+ T Cells, Their Differentiation
456 and Function. *Front Immunol*. 2017; **8**: 194.
- 457 35. Koutsakos M, Rowntree LC, Hensen L, Chua BY, van de Sandt CE, Habel JR, et al.
458 Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.
459 *Cell Rep Med*. 2021; **2**: 100208.

- 460 36. Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, et al.
461 Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell*.
462 2022; **185**: 493-512.e25.
- 463 37. Kang CK, Han GC, Kim M, Kim G, Shin HM, Song KH, et al. Aberrant hyperactivation of
464 cytotoxic T-cell as a potential determinant of COVID-19 severity. *International Journal of*
465 *Infectious Diseases*. 2020; **97**: 313–21.
- 466 38. Jiang Y, Wei X, Guan J, Qin S, Wang Z, Lu H, et al. COVID-19 pneumonia: CD8+ T and NK
467 cells are decreased in number but compensatory increased in cytotoxic potential. *Clinical*
468 *Immunology*. 2020; **218**: 108516.
- 469 39. Chen Q, Yu B, Yang Y, Huang J, Liang Y, Zhou J, et al. Immunological and inflammatory
470 profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. *Int*
471 *Immunopharmacol*. 2021; **97**: 107685.
- 472 40. Rha MS, Jeong HW, Ko JH, Choi SJ, Seo IH, Lee JS, et al. PD-1-Expressing SARS-CoV-2-
473 Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19.
474 *Immunity*. 2021; **54**: 44-52.e3.
- 475 41. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates
476 of protection against SARS-CoV-2 in rhesus macaques. *Nature*. 2021; **590**: 630–634.
- 477 42. Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate V v., Lang H, Lazarski CA, et
478 al. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody
479 Deficiency. *J Clin Immunol*. 2021; **41**: 1146–53.
- 480 43. Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells
481 contribute to survival in patients with COVID-19 and hematologic cancer. *Nat Med*. 2021;
482 **27**: 1280–9.
- 483 44. Wauters E, van Mol P, Garg AD, Jansen S, van Herck Y, Vanderbeke L, et al. Discriminating
484 mild from critical COVID-19 by innate and adaptive immune single-cell profiling of
485 bronchoalveolar lavages. *Cell Res*. 2021; **31**: 272–90.

- 486 45. Kroemer M, Spehner L, Vettoretti L, Bouard A, Eberst G, Pili Floury S, et al. COVID-19
487 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.
488 *Journal of Infection*. 2021; **82**: 282–327.
- 489 46. Khoo WH, Jackson K, Phetsouphanh C, Zaunders JJ, Alquicira-Hernandez J, Yazar S, et al.
490 Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with
491 mild/asymptomatic COVID-19. *Clinical Immunology*. 2023; **246**: 109209.
- 492 47. Gao Y, Ding M, Dong X, Zhang J, Kursat Azkur A, Azkur D, et al. Risk factors for severe
493 and critically ill COVID-19 patients: A review. *Allergy*. 2021; **76**: 428–55.
- 494 48. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human
495 vaccine immune responses. *Immunity & Ageing*. 2019; **16**.
- 496 49. Jalali S, Harpur CM, Piers AT, Auladell M, Perriman L, Li S, et al. A high-dimensional
497 cytometry atlas of peripheral blood over the human life span. *Immunol Cell Biol*. 2022; **100**:
498 805–821.
- 499 50. Zheng Y, Liu X, Le W, Xie L, Li H, Wen W, et al. A human circulating immune cell
500 landscape in aging and COVID-19. *Protein Cell*. 2020; **11**: 740-770.
- 501 51. Ashhurst TM, Marsh-Wakefield F, Putri GH, Spiteri AG, Shinko D, Read MN, et al.
502 Integration, exploration, and analysis of high-dimensional single-cell cytometry data using
503 Spectre. *Cytometry Part A*. 2022; **101**: 237–53.
- 504 52. Linderman GC, Rachh M, Hoskins JG, Steinerberger S, Kluger Y. Fast interpolation-based t-
505 SNE for improved visualization of single-cell RNA-seq data. *Nat Methods*. 2019; **16**: 243–
506 245.
- 507 53. Marsh-Wakefield F, Juillard P, Ashhurst TM, Juillard A, Shinko D, Putri GH, et al.
508 Peripheral B-cell dysregulation is associated with relapse after long-term quiescence in
509 patients with multiple sclerosis. *Immunol Cell Biol*. 2022; **100**: 453–467.
- 510
511

512 **Figure Legends**

513 **Figure 1. Variance in the T cell compartment explained by COVID-19 severity.** A) Principal
514 component analysis based on the relative abundance of 38 T cell populations in patients with
515 asymptomatic to critical COVID-19 (n = 35). Patient disease severity overlay on principal
516 component analysis where non-overlapping disease states represent a difference in the relative
517 abundance of T cell populations between groups. B) Variable contribution plot visualising the T cell
518 populations that contribute to the principal components. Arrow direction represents correlation,
519 where opposing direction is negative and adjacent arrows represent positive correlation between
520 variables. Differences between groups determined by FDR.

521

522 **Figure 2. Unbiased clustering of T cell compartment in severe and critical patients.** A) t-SNE
523 visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n
524 = 5) and critical (n = 3) patient. B) t-SNE visualisation of alterations in proportion of metaclusters
525 making up the T cell compartment between severe and critical disease. C) Heatmap plot showing
526 the relative expression of each marker on self-organised map metaclusters. D) Partial Least Squares
527 Discriminant Analysis of relative frequencies of 20 non-redundant CD4⁺ and CD8⁺ T cell
528 populations defined by automatic clustering. E) Christmas tree plot visualising the variables
529 contributing to variance between severe and critical disease as determined by PLS-DA F) Non-
530 parametric Mann-Whitney U test of proportions of metaclusters between severe and critical
531 infection patients; error lines represent median ± interquartile range.

532


533 **Figure 3. Differentiation status of CD4⁺ and CD8⁺ T cell compartments.** A) Summary bar plots
534 representing frequency of CD4⁺ and CD8⁺ T cell naïve and memory subsets between disease states
535 defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA}
536 (CCR7⁻CD45RO⁻). B) Frequency of CD4⁺ and CD8⁺ T_N and T_{EMRA} subsets C) Frequency of CD4⁺
537 and CD8⁺ T_{EMRA} cells expressing HLA-DR and PD-1. D) Frequency of total T_{FH} cells defined by
538 CXCR5^{hi}CD4⁺ phenotype, and CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ cT_{FH} cells. Difference between

539 groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of
540 experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent
541 median \pm interquartile range.

542


543 **Figure 4. Cytotoxic CD4⁺ and CD8⁺ T cells are expanded in critical infection.** **A)** Frequency of
544 GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells across disease states. **B)** Frequency of GZMB⁺PFN⁺ non-T_{FH}
545 cells (CXCR5^{-lo}) and T_{FH} cells (CXCR5^{hi}) as a proportion of all CD4⁺ T cells **C)** Frequency of
546 GZMB⁺PFN⁺ CD4⁺ T_{EMRA} cells as a proportion of parent **D)** Summary bar plot representing the
547 differentiation status of total CD4⁺ non-T_{FH} cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T cells
548 defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA}
549 (CCR7⁻CD45RO⁻) in critical infection patients (n = 3). **E)** Summary bar plot representing the
550 differentiation status of total CD4⁺ T_{FH} (CXCR5⁺) cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T_{FH}
551 cells by CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ (cT_{FH}) cell phenotype in critical infection patients (n = 3). **F)**
552 XY plot of correlation between GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells as a proportion of total CD4⁺
553 and CD8 T⁺ cells, respectively. Difference between groups determined by non-parametric Kruskal-
554 Wallis, with comparison of the rank mean of experimental groups by Original FDR method of
555 Benjamini and Hochberg; error bars represent median \pm interquartile range.

556



557


558 **Figure 1. Variance in the T cell compartment explained by COVID-19 severity.** A) Principal
559 component analysis based on the relative abundance of 38 T cell populations in patients with
560 asymptomatic to critical COVID-19 (n = 35). Patient disease severity overlay on principal
561 component analysis where non-overlapping disease states represent a difference in the relative
562 abundance of T cell populations between groups. B) Variable contribution plot visualising the T cell
563 populations that contribute to the principal components. Arrow direction represents correlation,
564 where opposing direction is negative and adjacent arrows represent positive correlation between
565 variables. Differences between groups determined by FDR.
566



567


568 **Figure 2. Unbiased clustering of T cell compartment in severe and critical patients. A)** t-SNE
 569 visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n
 570 = 5) and critical (n = 3) patient. **B)** t-SNE visualisation of alterations in proportion of metaclusters
 571 making up the T cell compartment between severe and critical disease. **C)** Heatmap plot showing
 572 the relative expression of each marker on self-organised map metaclusters. **D)** Partial Least Squares
 573 Discriminant Analysis of relative proportions of 20 non-redundant CD4+ and CD8+ T cell
 574 populations defined by automatic clustering. **E)** Christmas tree plot visualising the variables
 575 contributing to variance between severe and critical disease as determined by PLS-DA **F)** Non-
 576 parametric Mann-Whitney U test of proportions of metaclusters between severe and critical
 577 infection patients; error lines represent median ± interquartile range.

578




579

580 **Figure 3. Differentiation status of CD4⁺ and CD8⁺ T cell compartments.** A) Summary bar plots
 581 representing frequency of CD4⁺ and CD8⁺ T cell naïve and memory subsets between disease states
 582 defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁺CD45RO⁺), and T_{EMRA}
 583 (CCR7⁺CD45RO⁺). B) Frequency of CD4⁺ and CD8⁺ T_N and T_{EMRA} subsets C) Frequency of CD4⁺
 584 and CD8⁺ T_{EMRA} cells expressing HLA-DR and PD-1. D) Frequency of total T_{FH} cells defined by
 585 CXCR5^{hi}CD4⁺ phenotype, and CCR7⁺PD-1⁻ and CCR7⁺PD-1⁺ cT_{FH} cells. Difference between
 586 groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of
 587 experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent
 588 median ± interquartile range.
 589



590

591 **Figure 4. Cytotoxic CD4⁺ and CD8⁺ T cells are expanded in critical infection.** A) Frequency of
592 GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells across disease states. B) Frequency of GZMB⁺PFN⁺ non-T_{FH}
593 cells (CXCR5^{-lo}) and T_{FH} cells (CXCR5^{hi}) as a proportion of all CD4⁺ T cells C) Frequency of
594 GZMB⁺PFN⁺ CD4⁺ T_{EMRA} cells as a proportion of parent D) Summary bar plot representing the
595 differentiation status of total CD4⁺ non-T_{FH} cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T cells
596 defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA}
597 (CCR7⁻CD45RO⁻) in critical infection patients (n = 3). E) Summary bar plot representing the
598 differentiation status of total CD4⁺ T_{FH} (CXCR5⁺) cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T_{FH}
599 cells by CCR7⁺PD-1⁻ and CCR7⁺PD-1⁺ (cT_{FH}) cell phenotype in critical infection patients (n = 3). F)
600 Pearson correlation between GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells as a proportion of total CD4⁺
601 and CD8⁺ T⁺ cells, respectively. Difference between groups determined by non-parametric Kruskal-
602 Wallis, with comparison of the rank mean of experimental groups by Original FDR method of
603 Benjamini and Hochberg; error bars represent median ± interquartile range.
604




605

606 **Supplementary Figure 1. Gating strategy for T cells subsets.** Human peripheral blood
 607 mononuclear cells (PBMCs) were analysed by spectral cytometry. **A)** Dead cells, cell aggregates,
 608 and myeloid cells were excluded by LIVE/DEAD, time, FSC-H, FSC-A, and SSC-A. T cells were
 609 isolated by CD3⁺CD19⁻ and CD3⁺CD56⁻ phenotype to exclude B cells and NKT cells, respectively.
 610 **B)** T cells were divided into CD4⁺ and CD8⁺ T cells. CD4⁺ T cells were divided further into
 611 CXCR5^{-/lo} CD4⁺ non-T_{FH} cells and CXCR5^{hi} T_{FH} cells. T_{FH} cells were defined as cT_{FH} by CCR7
 612 PD-1⁺ and as CCR7⁺PD-1⁻ cells. CD4⁺ non-T_{FH} and CD8⁺ T cells were divided into naïve/memory
 613 subsets defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and
 614 T_{EMRA} (CCR7⁻CD45RO⁻). Flow plots of representative non-infected control sample COVIMM_093
 615 and performed in FlowJo v10.8.1.

616

617



618

619 **Supplementary Figure 2. Expression of lineage and functional markers on Fit-SNE of**
620 **metaclusters.** Relative expression of cellular marker expression on Fit-SNE visualisation of
621 FlowSOM automatic clustering of a subsample of T cells from each severe (n = 5) and critical (n =
622 3) patient.
623

624 Supplementary Table 1. Patient clinical characteristics

Peak disease status (n)	Median age (range)	Days post positive swab (range)
Asymptomatic (5)	30 (25-51)	11 (5-32)
Mild (18)	31 (12-60)	15 (5-49)
Moderate (4)	58 (55-79)	21 (14-28)
Severe (5)	49 (24-69)	14 (14-112)
critical (3)	65 (59-65)	28 (28)
Total	35 (12-79)	14 (5-12)

625

Product	Fluorophore	Clone	Detector	Species raised in	Source
CD3	BUV395	SK7	UV375_C	Mouse	BD Horizon™
Invitrogen LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit, for UV excitation	N/A	N/A	UV450	Mouse	Invitrogen
CD8 [†]	BUV496	RPA-T8	UV514	Mouse	BD Horizon™
PD-1 ^{††}	BUV737	EH12.2	UV737_	Mouse	BD Horizon™
CD19	BV510	HIB19	V510_	Mouse	BioLegend®
CD56	BV605	NCAM16.2	V598	Mouse	BD Biosciences®
HLA-DR ^{††}	BV650	G46-6	V660_C	Mouse	BD Biosciences®
Ki-67 ^{††}	BV711	Ki67	V720	Mouse	BioLegend®
CD45RO [†]	BV786	UCHL1	V780_A	Mouse	BioLegend®
CD4 [†]	PerCPCy5.5	RPA-T4	B695_A	Mouse	BioLegend®
Perforin ^{††}	PE	B-D48	YG582_D	Mouse	BioLegend®
CD197(CCR7) [†]	PECy7	G043H7	YG780_A	Mouse	BioLegend®
Granzyme B ^{††}	APC	QA16A02	R660_C	Mouse	BioLegend®
CXCR5 [†]	AF647	RF8B2	R679	Rat	BD Biosciences®

626 Supplementary Table 2. Antibody Panel

627 [†]Markers used for automatic clustering; ^{††} Intracellular markers